Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced Unresectable or Metastatic HCC
The purpose of this study is to evaluate whether treatment with RP2 can provide efficacy as 2L treatment combined with atezolizumab plus bevacizumab in patients with locally advanced unresectable, recurrent, and/or metastatic HCC.
Hepatocellular Carcinoma
BIOLOGICAL: RP2|BIOLOGICAL: Bevacizumab|BIOLOGICAL: Atezolizumab
Overall Response Rate per modified RECIST 1.1, The proportion of patients achieving a BOR of CR or PR per RECIST 1.1 as modified for use in this study among those that are evaluable for response., From Day 1 up to 3 years after first RP2 dose of last patient.
Number of patients with treatment-emergent adverse events (TEAEs)., The incidence of all TEAEs, From Day 1 up to 135 days after last dose.|ORR per RECIST modified for HCC (HCC mRECIST), The proportion of patients achieving a BOR of CR or PR per HCC-mRECIST among those that are evaluable for response, From Day 1 up to 3 years after first RP2 dose of last patient|Duration of response (DOR), The time from a tumor response, either a CR or PR (whichever is recorded first), until the date of PD, which was subsequently confirmed, or with no further follow up, or death due to any cause, whichever occurs first., From Day 1 up to 3 years after first RP2 dose of last patient.
The purpose of this study is to evaluate whether treatment with RP2 can provide efficacy as 2L treatment combined with atezolizumab plus bevacizumab in patients with locally advanced unresectable, recurrent, and/or metastatic HCC.